Skip to main content

BridgeBio Pharma to Participate in November Investor Events

PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences: 

  • Jefferies Health Care Conference, London, UK: November 15th at 9:40 am ET
  • Evercore ISI HealthCONx Conference, Virtual: November 30th at 10:05 am ET 

To access the live webcast of BridgeBio’s presentations, please visit the “Events” page within the Investors section of the BridgeBio website at A replay of the webcasts will be available on the BridgeBio website for 90 days following the event. 

About BridgeBio Pharma, Inc. 
BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit and follow us on LinkedIn and Twitter

BridgeBio Contact: 
Vikram Bali

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.